The DOI matches its Crossref record, with a small difference in title or year; 26 of the 26 references it cites were found in a registry or an index.
Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study
Abstract
Minocycline is a caspase inhibitor, decreases inducible nitric oxide synthase, and has been shown to delay disease in a mouse model of neuropsychiatric disorders. Recently, we reported the antipsychotic effects of minocycline in patients with schizophrenia. In a pilot investigation, we administered minocycline (150 mg/d) for 4 weeks as an open-label adjunct to antipsychotic medication to 22 patients with schizophrenia. The Positive and Negative Syndrome Scale for schizophrenia showed statistically significant and robust clinical improvements with minocycline treatment, which were maintained at follow-up evaluation 4 weeks after the end of minocycline treatment. There were no adverse events. These results suggest that minocycline may be a safe and effective adjunct to antipsychotic medications, and that augmentation with minocycline may prove to be a viable strategy for "boosting" antipsychotic efficacy and for treating schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Various clinical trials have been conducted using minocycline alone or as an adjunct to risperidone in patients with schizophrenia and have demonstrated overall improvement in negative symptoms and executive functioning (Miyaoka et al., 2008; Levkovitz et al., 2010; Khodaie-Ardakani et al., 2014).”
From The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders (2018) · cites this paper as Miyaoka et al., 2008
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Microglia: Intrinsic immuneffector cell of the brain
Gehrmann, J., Matsumoto, Y., & Kreutzberg, G. W. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(94)00015-h · Cited by 1,111
Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,060
Yrjänheikki, J., Kauppinen, T. M., Keinänen, R., Goldsteins, G., Chan, P. H., & Koıstınaho, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13496 · Cited by 1,040
Tikka, T., Fiebich, B. L., Goldsteins, G., Keinänen, R., & Koistinaho, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02580.2001 · Cited by 958
Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L. G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251341998 · Cited by 789
Tikka, T., & Koıstınaho, J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7527 · Cited by 539
The Promise of Minocycline in Neurology
Yong, V. W., Wells, J., Giuliani, F., Casha, S., Power, C., & Metz, L. M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00937-8 · Cited by 518
Research works printed but not linked: 1
- German, 2004, Regulation of apoptosis by typical and atypical antipsychotics in rat frontal cortex., Eur Neuropsychopharmacol, 55, 214S
Cited by
Sorted by citations
Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment
Khandaker, G. M., Cousins, L., Deakin, J., Lennox, B. R., Yolken, R., & Jones, P. B. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00122-9 · Cited by 926
Neuroinflammation and psychiatric illness
Najjar, S., Pearlman, D. M., Alper, K., Najjar, A., & Devinsky, O. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-43 · Cited by 733
Glutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
Inflammasome signaling affects anxiety- and depressive-like behavior and gut microbiome composition
Wong, M.-L., Inserra, A., Lewis, M. D., Mastronardi, C. A., Leong, L., Choo, J., Kentish, S., Xie, P., Morrison, M., Wesselingh, S. L., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.46 · Cited by 568
Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study
Doorduin, J., de Vries, E. F. J., Willemsen, A. T. M., de Groot, J. C., Dierckx, R., & Klein, H. C. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.066647 · Cited by 561
Metadata
- Authors
- Miyaoka, T., Yasukawa, R., Yasuda, H., Hayashida, M., Inagaki, T., & Horiguchi, J.
- Affiliations
- Shimane University (JP)
- Corresponding author
- Miyaoka, Tsuyoshi
- Venue
- Clinical Neuropharmacology
- Published
- 2008-09
- Volume
- 31
- Issue
- 5
- Pages
- 287-292
- ISSN
- 0362-5664 (ISSN-L)
- OpenAlex
- W2018922612
- Cited by
- 146
- References
- 26
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 5 · 2019: 5 · 2018: 14 · 2017: 7 · 2016: 9 · 2015: 14 · 2014: 15 · 2013: 14 · 2012: 13
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- minocycline, schizophrenia, adjunctive therapy, antipsychotic augmentation, caspase inhibition, inducible nitric oxide synthase, antipsychotic efficacy
- MeSH terms
- Adult, Female, Follow-Up Studies, Humans, Male, Middle Aged, Minocycline, Pilot Projects, Schizophrenia, Schizophrenic Psychology, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
